Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Total 13F shares
-
39,323,641
-
Share change
-
+7,143,039
-
Total reported value
-
$1,429,414,516
-
Put/Call ratio
-
23%
-
Price per share
-
$36.35
-
Number of holders
-
155
-
Value change
-
+$260,798,405
-
Number of buys
-
103
-
Number of sells
-
39
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q1 2024
As of 31 Mar 2024,
Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) was held by
155 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,323,641 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, BlackRock Inc., MORGAN STANLEY, TANG CAPITAL MANAGEMENT LLC, Cormorant Asset Management, LP, COWEN AND COMPANY, LLC, VANGUARD GROUP INC, Frazier Life Sciences Management, L.P., and JENNISON ASSOCIATES LLC.
This page lists
155
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.